PF-3882845 also binds to the progesterone receptor (the binding IC50: 310 nM). PF-3882845 is a remarkably high affinity selective and orally efficacious mineralocorticoid receptor (MR binding IC50=2.7 nM) antagonist for hypertension and nephropathy.

PF-3882845 shows moderate oral bioavailability (F 86%) following oral administration (2 mg/kg) in male Sprague-Dawley rats. PF-3882845 displays terminal elimination half-lives (T1/2 1.7 h) due to high plasma clearance (CL 9.8 mL/min/kg) combined with large volumes of distribution (Vdss 1.4 mL/kg respectively) following intravenous administration (2 mg/kg) in male Sprague-Dawley rats. PF-3882845 decreases blood pressure, decreases urinary albumin, and protects kidney in Dahl SS rat [1].

1023650-66-9

C24H22ClN3O2

419.9

PF-3882845

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years